Arecor Therapeutics – discounted fundraising, how much really for “revenue growth across the business”?
Describing itself as a “biopharmaceutical group advancing today's therapies to enable healthier lives”, Arecor Therapeutics (AREC) has announced a proposed fundraising for “revenue growth across the business, working capital and balance sheet strength with a view toward delivering shareholder value”. What of this from a current 92.5p share price?


